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ABSTRACT 
Quality by Design is the modern approach for quality of pharmaceuticals. It describes use of Quality by Design to ensure quality of 
Pharmaceuticals. In this review, the Quality by Design is described and some of its elements identified. Process parameters and quality 
attributes are identified for each unit operation. Benefits, opportunities and steps involved in Quality by Design of Pharmaceutical products are 
described. It is based on the ICH Guidelines Q8 for pharmaceutical development,  Q9 for quality risk management, Q10 for pharmaceutical 
quality systems. It also gives application of Quality by Design in pharmaceutical development and manufacturing of pharmaceuticals. It includes 
the Quality target product profile, critical quality attributes and key aspects of Quality by Design. It also gives comparison between product 
quality by end product testing and product quality by Quality by Design. The foundation of Quality by Design is ICH Guideline s. 
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INTRODUCTION  
Quality means fitness for intended use. Pharmaceutical 
quality refers to product free of contamination and 
reproducibly delivers the therapeutic benefit promised in the 
label to the consumer. The Quality of the pharmaceutical 
product can be evaluated by in vivo or in vitro performance 
tests. Quality by design assures in vitro product performance 
and In vitro product performance provides assurance of in 
vivo product performance. “Hence Quality by design relate to 
Product Performance”. (1) 
Quality by Design (QbD) is a modern, scientific approach that 
formalizes product design, automates manual testing, and 
streamlines troubleshooting. It uses a systematic approach to 
ensure quality by developing a thorough understanding of 
the compatibility of a finished product to all of the 
components and processes involved in manufacturing that 
product. Instead of relying on finished product testing alone, 
QbD provides insights upstream throughout the 
development process. As a result, a quality issue can be 
efficiently analyzed and its root cause quickly identified. 
QbD requires identification of all critical formulation 
attributes and process parameters as well as determining the 
extent to which any variation can impact the quality of the 
finished product. The more information generated on the 
impact – or lack of impact – of a component or process on a 
product’s quality, safety or efficacy, the more business 
flexibility Quality by Design provides.  
While medicine is well known as special goods, the 
development of pharmaceutical industry is based on 
innovation and manufacturing. However, there are lots of 
complaints from pharmaceutical industry about the strict 
rules. In current quality by test (QbT) system, product 
quality is ensured by following a sequence of steps, including 
raw material testing, fixed drug product manufacturing 
process, and end product testing. It is only when all the 
specifications of the FDA or other standards are complied 
with that the materials can be used for manufacturing or 
come into market. If not, they need to be reprocessed. Root 
causes for failure are usually not well understood due to the 
poor process understanding and uncertainty about how 
characteristics of substances impacts target product profile. 
As a result, the manufacturers have to restart the procedure 
until the root causes of failure are understood and addressed 
or FDA approves supplements to revise (e.g., widen) the 
acceptance criteria to pass the previously failed batches. This 
causes poor cost-efficiency and product variation, which may 
lead to poor drug safety.  
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Figure. 1    Quality by Thought (QbT) 
 
Definition 
The pharmaceutical Quality by Design (QbD) is a systematic 
approach to development that begins with predefined 
objectives and emphasizes product and process 
understanding and process control, based on sound science 
and quality risk management. Quality by Design (QbD) is 
emerging to enhance the assurance of safe, effective drug 
supply to the consumer, and also offers promise to 
significantly improve manufacturing quality performance.(2) 
Objectives of QbD: 
• The main objectives of QbD is to ensure the quality 
products, for that product & process characteristics 
important to desired performance must be resulting 
from a combination of prior knowledge & new 
estimation during development.  
• From this knowledge & data process measurement & 
desired attributes may be constructed. 
• Experimental study would be viewed as positive 
performance testing of the model ability through 
Design space.  
• Ensures combination of product & process knowledge 
gained during development. 
QbD BY PHARMACEUTICALS (3) 
Even though the pharmaceutical industry has focus on 
quality, it has failed to keep up with other industries in terms 
of manufacturing efficiency and productivity.  
Current scenario in the Pharmaceutical Industry: 
• Cost of revalidation  
• Off‐line analysis for in‐process ‐ need based  
• Product specifications as primary means of control  
• Unpredictable Scale‐up issues  
• Inability to understand failures  
Systematic approach to development:  
• That begins with predefined objectives  
• Emphasizes products and process understanding  
• Process control   
Benefits of QbD 
• QbD is good Business 
• Eliminate batch failures  
• Minimize deviations and costly investigations  
• Avoid regulatory compliance problems 
• Organizational learning is an investment in the future  
• QbD is good Science  
• Better development decisions  
• Empowerment of technical staff  
Opportunities  
• Efficient, agile, flexible system  
• Increase manufacturing efficiency, reduce costs and 
project rejections and waste 
• Build scientific knowledge base for all products  
• Better interact with industry on science issues 
• Ensure consistent information  
• Incorporate risk management 
Bhise et al                                                                                                       Journal of Drug Delivery & Therapeutics. 2019; 9(3-s):1137-1146 
ISSN: 2250-1177                                                                                  [1139]                                                                                    CODEN (USA): JDDTAO 
For industry: 
• Better understanding of the process.  
• More efficient and effective control of change. 
• Return on investment / cost savings 
• Less Batch failure.  
• Ensure better design of products with less problems in 
manufacturing.  
• Allows for continuous improvement in products & 
manufacturing process 
For FDA: 
• Enhances scientific base for analysis.  
• Provide better consistency.  
• Provide for more flexibility in decision making.  
• Ensures decisions made on science & not on observed 
information. 
STEPS INVOLVED IN QUALITY BY DESIGN 
PRODUCTS 
• Development of new molecular entity  
• Preclinical study  
• Nonclinical study  
• Clinical Study  
• Scale up  
• Submission  for market Approval  
• Manufacturing  
• Design Space  
• Process Analytical Technology  
• Real time Quality Control 
• Control Strategy  
• Risk based decision  
• Continuous Improvement  
• Product performance  
   Seven steps of quality by design start up plan  
• Hire an independent Quality by design expert.  
• Audit your organization and process with the expert 
conducting a gape analysis.  
• Hold a basic quality by design workshop with all your 
personal.  
• Review the expert’s report and recommendation.  
• Draft an implementation plan, timelines and estimated 
costs.  
• Assign the resources (or contract out).  
• Retain the independent expert as your “Project 
Assurance” advisor.  
 Quality by design (QbD) and well understood product 
and processes 
• All critical sources of variability are identified and 
explained. 
• Variability is controlled by the process.  
• Product quality attributes can be accurately and 
reliably predicted over the design space established for 
materials used, process parameters, environmental and 
other conditions.  
• To gain enhanced knowledge of product performance 
over a range of material attributes, manufacturing 
process options and process parameters considering 
appropriate use of quality risk management principles. 
QbD development process include :(4,5) 
• Begin with a target product profile that describes the 
use, safety and efficacy of the product 
• Define a target product quality profile that will be used 
by formulators and process engineers as a quantitative 
surrogate for aspects of clinical safety and efficacy 
during product development 
• Gather relevant prior knowledge about the drug 
substance, potential excipients and process operations 
into a knowledge space. Use risk assessment to 
prioritize knowledge gaps for further investigation 
• Design a formulation and identify the critical material 
(quality) attributes of the final product that must be 
controlled to meet the target product quality profile. 
• Design a manufacturing process to produce a final 
product having these critical material attributes. 
• Identify the critical process parameters and input (raw) 
material attributes that must be controlled to achieve 
these critical material attributes of the final product. 
Use risk assessment to prioritize process parameters 
and material attributes for experimental verification. 
Combine prior knowledge with experiments to 
establish a design space or other representation of 
process understanding. 
• Establish a control strategy for the entire process that 
may include input material controls, process controls 
and monitors, design spaces around individual or 
multiple unit operations, and/or final product tests. 
The control strategy should encompass expected 
changes in scale and can be guided by a risk 
assessment. 
• Continually monitor and update the process to assure 
consistent quality. 
• Design of experiments (DOE), risk assessment, and 
process analytical technology (PAT) are tools that may 
be used in the QbD process when appropriate. They are 
not check-box requirements. 
ICH Guidelines Q8 for Pharmaceutical Development, Q9 for 
Quality Risk Management, Q10 for Quality systems are 
foundation of QbD (Figure:2 ) 
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Figure 2. ICH guidelines of QbD 
Quality by Design (6,7,8,9) 
• Concepts aligned  
• Design Space - Key to understanding  
• Process robustness   
• Design of Experiments (DOE)  
• Quality management Quality management 
Advantages of QbD 
• It provides a higher level of assurance of drug product 
quality. 
• It offers cost savings and efficiency for the pharmaceutical 
industry. 
• It increases the transparency of the sponsor understands 
the control strategy for the drug product to obtain approval 
and ultimately commercialize. 
• It makes the scale-up, validation and commercialization 
transparent, rational and predictable. 
• It facilitates innovation for unmet medical needs. 
• It increases efficiency of pharmaceutical manufacturing 
processes and reduces manufacturing costs and product 
rejects. 
• It minimizes or eliminates potential compliance actions, 
costly penalties, and drug recalls. 
• It offers opportunities for continual improvement. 
• It provides more efficiency for regulatory oversight: 
• It streamlines post approval manufacturing changes and 
regulatory processes. 
• It more focused post approval CGMP inspections 
• It enhances opportunities for first cycle approval. 
• It facilitates continuous improvement and reduces the CMC 
supplement. 
• It enhances the quality of CMC and reduces the CMC review 
time. 
 
Benefits for Industry:(10) 
• Better understanding of the process. 
• Less batch failure. 
• More efficient and effective control of change. 
• Return on investment / cost savings. 
Additional opportunities: 
An enhance QbD approach to pharmaceutical development 
provides opportunities for more flexible regulatory 
approaches. 
Ex: Manufacturing changes within the approved design 
space without further regulatory review. 
• Reduction of post-approval submissions. 
• Better innovation due to the ability to improve 
processes without resubmission to the FDA when 
remaining in the Design Space. 
• More efficient technology transfer to manufacturing. 
• Greater regulator confidence of robust products. 
• Risk-based approach and identification. 
• Innovative process validation approaches. 
• Less intense regulatory oversight and less post-
approval submissions. 
• For the consumer, greater drug consistency. 
• More drug availability and less recall. 
• Improved yields, lower cost, less investigations, 
reduced testing, etc. 
• Time to market reductions: from 12 to 6 years realized 
by amongst others. 
• First time right: lean assets management. 
• Continuous improvement over the total product life 
cycle (i.e. controlled, patient guided variability). 
• Absence of design freeze (no variation issues). 
• Less validation burden. 
• Real time controls (less batch controls). 
• Realistic risk perceptions. 
• Contributes substantially to realize the better, cheaper 
and safer mandate. 
QbD activities within FDA(11,12,13,14) 
Specifically, the following activities are guiding the overall 
implementation of QbD: 
• In FDA’s Office of New Drug Quality Assessment 
(ONDQA), a new risk-based pharmaceutical quality 
assessment system (PQAS) was established based on 
the application of product and process understanding. 
• Implementation of a pilot program to allow 
manufacturers in the pharmaceutical industry to 
submit information for a new drug application 
demonstrating use of QbD principles, product 
knowledge, and process understanding. In 2006, Merck 
& Co.’s Januvia became the first product approved 
based upon such an application. 
• Implementation of a Question-based Review (QbR) 
Process has occurred in CDER’s Office of Generic Drugs. 
DESIRED 
STATE 
Pharmaceuti
cal 
Developmen
t (Q8) 
Quality risk 
managemen
t (Q9) 
Quality 
systems 
(Q10) 
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• CDER’s Office of Compliance has played an active role 
in complementing the QbD initiative by optimizing pre-
approval inspectional processes to evaluate 
commercial process feasibility and determining if a 
state of process control is maintained throughout the 
lifecycle, in accord with the ICH Q10 lifecycle Quality 
System. 
• Implementation of QbD for a Biologic License 
Application (BLA) is progressing. 
While QbD will provide better design predictions, there is 
also a strong recognition that industrial scale-up and 
commercial manufacturing experience provides new and 
very important knowledge about the process and the raw 
materials used therein. FDA is aware that knowledge is not 
static and builds throughout the manufacturing lifecycle. 
FDA’s release of the Process Validation guidance in January 
2011 notes the need for companies to continue benefiting 
from knowledge gained, and continually improve throughout 
the process lifecycle by making adaptations to assure root 
causes of manufacturing problems are quickly corrected. 
This vigilant and nimble approach is explained by FDA to be 
essential to best protect the consumer (patient). 
International Conference on Harmonization. (ICH)(15-
22) 
Relevant documents from the International Conference on 
Harmonization of Technical Requirements for Registration of 
Pharmaceuticals for Human Use. (ICH) 
• Pharmaceutical Development Q8 (R2) 
• Quality Risk Management Q9 
• Pharmaceutical Quality System Q10 
The difference between QbD for NDA and ANDA products is 
most apparent at the first step of the process. For an NDA, 
the target product profile is under development while for the 
ANDA product the target product profile is well established 
by the labelling and clinical studies conducted to support the 
approval of the reference product. 
Quality by design (QbD) encompasses designing and 
developing formulations and manufacturing processes which 
ensures predefined product specifications. The concept of 
quality by design (QbD) has been recently adopted in the 
pharmaceutical industry through several initiatives {e.g., ICH 
Q81, Q92and Q103, and the new regulatory documents, 
Process Analytical Technology (PAT)5, FDAs cGMP for the 
21st Century4}. The general aim is to switch from the quality 
by testing (QbT) paradigm previously implemented in the 
pharmaceutical industry to a development aimed at 
improving the understanding of the processes and the 
products and hence improving product quality, process 
efficiency and regulatory flexibility.  
The aim of pharmaceutical development is to design a quality 
product and its manufacturing process to consistently 
deliver the intended performance of the product. The 
information and knowledge gained from pharmaceutical 
development studies and manufacturing experience provide 
scientific understanding to support the establishment of the 
design space, specifications, and manufacturing controls. 
Information from pharmaceutical development studies can 
be a basis for quality risk management. It is important to 
recognize that quality cannot be tested into products; i.e., 
quality should be built in by design. Changes in formulation 
and manufacturing processes during development and 
lifecycle management should be looked upon as 
opportunities to gain additional knowledge and further 
support establishment of the design space. Similarly, 
inclusion of relevant knowledge gained from experiments 
giving unexpected results can also be useful. 
The Pharmaceutical Development section should describe 
the knowledge that establishes that the type of dosage form 
selected and the formulation proposed are suitable for the 
intended use. This section should include sufficient 
information in each part to provide an understanding of the 
development of the drug product and its manufacturing 
process1. The Food and Drug Administration (FDA) Office of 
Generic Drugs (OGD) has developed a question based review 
(QbR) for its chemistry, manufacturing and controls (CMC) 
evaluation of Abbreviated New Drug Applications (ANDAs). 
QbR is a new quality attributes. It is a practical 
implementation of some underlying concepts and principles 
outlined by the FDA’s Pharmaceutical CGMPs for the twenty 
first century and quality by design (QbD) initiatives6. Figure 
1, which illustrates the different phases during the life cycle 
of a pharmaceutical process: define, design, characterize, 
validate, and monitor and control. The final link between 
“monitor and control” and “define” represents process 
changes that are initiated based on process improvement 
opportunities identified during process monitoring or 
introduced otherwise to improve process performance or 
robustness. Changes originating in this manner would again 
go through the cycle illustrated in Fig.3 
 
Fig 3: Illustration of the different steps in development 
of a pharmaceutical product. Pharmaceutical Quality by 
Design 
Pharmaceutical Quality by Design ICH Q8 defines quality as 
“The suitability of either a drug substance or drug product 
for its intended use. This term includes such attributes as the 
identity, strength, and purity. “ICH Q8 guideline states that 
Quality by Design is a systematic approach to development 
that begins with predefined objectives and emphasizes 
product and process understanding and process control, 
based on sound science and quality risk management”. 
ICH Guidelines Q8 for Pharmaceutical Development, Q9 for 
Quality Risk Management, Q10 for Quality systems are 
foundation of QbD (Fig. 2) “Product testing alone is not 
sufficient to assure that a process consistently produces a 
product with predetermined specifications. Adequate 
process design; knowledge and control of factors that 
produce process variability and successful validation studies, 
in conjunction with product testing, provide assurance that 
the process will produce a product with the required quality 
characteristics”.
 
Define 
Design 
Characterize  Validate 
Monitor & 
Control 
Bhise et al                                                                                                       Journal of Drug Delivery & Therapeutics. 2019; 9(3-s):1137-1146 
ISSN: 2250-1177                                                                                  [1142]                                                                                    CODEN (USA): JDDTAO 
Table 1: Difference between current approach and Qbd approach 
               Current Approach QbD Approach 
Quality is assured by testing and inspection. Quality is built into product & process by design and 
based on scientific understanding. 
It includes only data intensive submission which 
includes disjointed information without “big picture”. 
It includes Knowledge rich submission which shows 
product knowledge & process understanding. 
Here, any specifications are based on batch history. Here, any specifications based on product performance 
requirements. 
Here there is “Frozen process,” which always 
discourages changes. 
Here there is Flexible process within design space which 
allows continuous improvement. 
It focuses on reproducibility which often avoids or 
ignores variation. 
It focuses on robustness which understanding & control 
variation. 
 
There are several statements about the elements of QbD, the 
most widely accepted is that, QbD consists of the following 
parameters. 
ELEMENTS OF QbD :(23-29) 
1) Quality Target Product Profile (QTPP): 
It  including dosage form, delivery systems, dosage 
strength(s), etc. It is a prospective summary of quality 
characteristics of a drug product to be achieved, taking into 
account dosage strength(s) and container closure system of 
the drug product, together with the attributes affecting 
pharmacokinetic characteristics (e.g., dissolution, 
aerodynamic performance) and drug product quality criteria 
(e.g., sterility, purity, stability and drug release) appropriate 
for the intended marketed product. 
QTPP has been defined as a “prospective and dynamic 
summary of the quality characteristics of a drug product that 
ideally will be achieved to ensure that the desired quality, 
and thus the safety and efficacy, of a drug product is 
realized”. This includes dosage form and route of 
administration, dosage form strength(s), therapeutic moiety 
release or delivery and pharmacokinetic characteristics (e.g., 
dissolution and aerodynamic performance) appropriate to 
the drug product dosage form being developed and drug 
product-quality criteria (e.g. sterility and purity) 
appropriate for the intended marketed product. 
The role of target product profile (TPP) is to serve as a tool 
for “quality planning” for the drug product with “the end in 
mind” i.e. a summary of the drug development program 
described in the context of prescribing information goals. A 
quality target product profile (QTPP) is a term which is a 
natural extension of TPP for product quality .A QTPP relates 
to the quality of a drug substance or the drugs products that 
is necessary to deliver a desired therapeutic effect .QTPP is a 
predetermined summary of the characteristics of the drug 
product that will ideally be essential to ensure the desired 
quality with respect to safety and efficacy of the product. 
These predetermined QTPP evolve over time during drug 
development and may be modified to incorporate new 
knowledge, as is warranted by ongoing clinical studies such 
a dose effect and toxicology data. 
The Quality Target Product Profile (QTPP) is a term that is a 
natural extension of TPP for product quality. It is the quality 
characteristics that the drug product should possess in order 
to reproducibly deliver the therapeutic benefit promised in 
the label. The TPQP guides formulation scientists to 
establish formulation strategies and keep formulation efforts 
focused and efficient. TPQP is related to identity, assay, 
dosage form, purity, stability in the label. Biopharmaceutical 
properties of drug substance include physical, chemical, and 
biological properties. A typical QTPP of an immediate 
release solid oral dosage form would include: 
- Tablet Characteristics 
- Identity 
- Assay and Uniformity 
- Purity/Impurity 
- Stability, and 
- Dissolution 
The concept of TPP in this form and its application is novel 
in the QbD paradigm. TPP forms the basis for product design 
in the following way.   
• Dosage form   
• Route of administration  
• Strength, maximum and minimum  
• Release/delivery of the drug  Pharmacological 
characteristic  
• Drug product quality criteria 
• Pharmaceutical elegance 
Critical Quality Attribute (CQA): 
It including physical, chemical, biological, or microbiological 
properties or characteristics of an output material including 
finished drug product. Potential drug product CQAs derived 
from the QTPP and/or prior knowledge are used to guide the 
product and process development and they should be within 
an appropriate limit, range, or distribution to ensure the 
desired product quality. 
Once TPP has been identified, the next step is to identify the 
relevant CQAs. A CQA has been defined as “a physical, 
chemical, biological, or microbiological property or 
characteristic that should be within an appropriate limit, 
range, or distributed to ensure the desired product quality” 
Identification of CQAs is done through risk assessment as 
per the ICH guidance Q9. Prior product knowledge, such as 
the accumulated laboratory, nonclinical and clinical 
experience with a specific product-quality attribute, is the 
key in making these risk assessments. Such knowledge may 
also include relevant data from similar molecules and data 
from literature references. This information provides a 
rationale for relating the CQA to product safety and efficacy. 
The use of robust risk assessment methods for identification 
of CQAs is novel to the QbD paradigm.Critical quality 
attributes are defined as physical, chemical, biological or 
microbiological properties or characteristics that need to be 
controlled to ensure product quality.( According to ICH Q8) 
CQAs as physical, chemical, biological or microbiological 
properties or characteristics that should be within an 
appropriate limit, range, or distribution to ensure the 
desired product quality. CQA has been used by some to 
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describe elements of the TPQP while others have used CQA 
to describe mechanistic factors that determine product 
performance. Thus CQA is used to describe both aspects of 
product performance and determinants of product 
performance. 
Once TPQP has been identified, the next step is to identify 
the relevant CQAs. A CQA has been defined as “a physical, 
chemical, biological, or microbiological property or 
characteristic that should be within an appropriate limit, 
range, or distributed to ensure the desired product quality” 
Identification of CQAs is done through risk assessment as 
per the ICH guidance Q9. Prior product knowledge, such as 
the accumulated laboratory, nonclinical and clinical 
experience with a specific product-quality attribute, is the 
key in making these risk assessments. Such knowledge may 
also include relevant data from similar molecules and data 
from literature references.   
This information provides a rationale for relating the CQA to 
product safety and efficacy. The use of robust risk 
assessment methods for identification of CQAs is novel to the 
QbD paradigm CQAs of solid oral dosage forms are typically 
those aspects affecting product purity, strength, drug release 
and stability. CQAs for other delivery systems can 
additionally include more product specific aspects, such as 
aerodynamic properties for inhaled products, sterility for 
parentral , and adhesion properties for transdermal patches . 
For drug substances, raw materials and intermediates, the 
CQAs can additionally include those properties (e.g., particle 
size distribution, bulk density) that affect drug product 
CQAs. 
3) Critical Material Attributes (CMAs):  
 including physical, chemical, biological, or microbiological 
properties or characteristics of an input material. CMAs 
should be within an appropriate limit, range, or distribution 
to ensure the desired quality of that drug substance, 
excipient, or in-process material. 
 4) Critical Process Parameters (CPPs): 
Parameters monitored before or in process that influence 
the appearance, impurity, and yield of final product 
significantly.During the QbD process, product design and 
understanding include the identification of CMAs, which are 
different from CQAs. CQAs are for output materials while 
CMAs are for input materials including drug substance, 
excipients, in-process materials. The CQA of an intermediate 
may become a CMA of the same intermediate for a 
downstream manufacturing step. While process design and 
understanding include the identification of CPPs and a 
thorough understanding of scale-up principles, linking CMAs 
and CPPs to CQAs is of special importance. From the 
viewpoint of QbD, CMAs and CPPs can vary within the 
established Design Space without significant influence on 
CQAs, and as a result, the quality of the final product will 
meet the QTPP.  
 
 
Figure 4. 
5) Risk assessment 
Risk assessment is a systematic process of organizing 
information to support a risk decision to be made within a 
risk management process. It consists of the identification of 
hazards and the analysis and evaluation of risks associated 
with exposure to those hazards. It is the first step of quality 
risk management process; the other two steps are risk 
control and risk review. Risk control includes decision 
making to reduce and/or accept risks. The purpose of risk 
control is to reduce the risk to an acceptable level. At the 
final stage, the output/results of the risk management 
process should be reviewed to take into account new 
knowledge and experience. Throughout the risk 
management process, risk communication, the sharing of 
information about risk and risk management between the 
parties (including regulators and industry, industry and the 
patient, within a company, industry or regulatory authority, 
etc.), should be ongoing at any stage of the risk management 
process. The included information might relate to the 
existence, nature, form, probability, severity, acceptability, 
control, treatment, detectability or other aspects of risks to 
quality . 
A key objective of risk assessment in pharmaceutical 
development is to identify which material attributes and 
process parameters affect the drug product CQAs, that is, to 
understand and predict sources of variability in the 
manufacturing process so that an appropriate control 
strategy can be implemented to ensure that the CQAs are 
within the desired requirements. 
The identification of critical process parameters (CPP) and 
critical material attributes is an iterative process and occurs 
throughout development. During the initial phases of 
development, prior knowledge serves as the primary basis 
for the designation as there is not sufficient process/product 
understanding on the product under development. 
Therefore, the risks identified at the initial phases are 
perceived risks and as further process/product 
understanding is gained, the actual risks become clearer and 
a control strategy can be better defined. The risk assessment 
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tools used in earlier phases of development therefore tend to 
be more qualitative and serve as a means to prioritize the 
experimentation. 
It is nothing but linking material attributes and process 
parameters to CQAs. ICH Q9 Quality Risk Management 
indicates that, the manufacturing and use of a drug product 
necessarily lead to some degree of risk. The evaluation of the 
risk of quality should be based on scientific knowledge and 
link to the therapeutic benefit to the patient. The level of 
effort, formality and documentation of the quality risk 
management process should be proportionate with the level 
of risk. Performing a risk assessment before pharmaceutical 
development helps manufacturers decide which studies to 
conduct. Study results determine which variables are critical 
and which are not, which then guide the establishment of 
control strategies for in-process, raw-material, and final 
testing. 
Several applications in the CMC pilot included risk 
assessments, especially for the drug product by linking input 
and process variables to CQAs. Tools used in the risk 
assessment included the Ishikawa or Fishbone diagram, 
failure mode effect analysis (FMEA), Pareto analysis. An 
Ishikawa or Fishbone diagram is used to identify all potential 
variables, such as raw materials, compression parameters, 
and environmental factors, which can have an impact on a 
particular CQA such as tablets hardness. An FMEA can be 
used to rank the variables based on risk (i.e., a combination 
of probability, severity, and detectability) and to select the 
process parameter with higher risks for further studies to 
gain greater understanding of their effects ion CQAs 
There are three components of risk assessment, that is, risk 
identification, risk analysis and risk evaluation.  
(1) Risk Identification: The systematic use of information to 
identify potential sources of harm (hazards) that are 
referring to the risk question or problem description, which 
can include historical data, theoretical analysis, informed 
opinions, and the concerns of stakeholders; 
 (2) Risk Analysis: The estimation of the risk associated with 
the identified hazards;  
(3) Risk Evaluation: The comparison of the estimated risk to 
given risk criteria using a quantitative or qualitative scale to 
determine the significance of the risk. 
ICH Q9 provides a non-exhaustive list of 9 common risk 
management tools as follows: 
 (1) Basic risk management facilitation methods (Ishikawa 
fishbone diagram, flowcharts, check sheets, etc.); 
 (2) Fault tree analysis;  
(3) Risk ranking and filtering;  
(4) Preliminary hazard analysis; 
 (5) Hazard analysis and critical control points;  
(6) Failure mode and effects analysis (FMEA);  
(7) Failure mode, effects, and criticality analysis (FMECA);  
(8) Hazard operability analysis;  
(9) Supporting statistical tools. 
According to the implementation of QbD, risk assessment has 
the priority over DoE. Among the tools, Ishikawa fishbone 
diagram  and FMEA are widely used approaches for risk 
assessment, either separately  or in combination . Taking the 
preparation of extruded particles as an example, the 
Ishikawa diagram is shown in . The risk factors in the 
fishbone diagram are classified into broad categories, while 
the FMEA could identify the failure modes that have the 
greatest chance of causing product failure, which means each 
of the factors in the Ishikawa fishbone diagrams will be 
ranked later in the FMEA analysis. The FMEA method can be 
used to perform the quantitative risk assessment, identifying 
the CQAs that have the greatest chance of causing product 
failure. The outcome of an FMEA are risk priority numbers 
(RPN) for each combination of failure mode severity, 
occurrence probability, and likelihood of detection. 
6) Design of experiment (DoE) 
To carry out the design of experiment, the risk assessment 
should be taken into function first. A structured, organized 
method for determining the relationship between factors 
affecting a process and the output of that process is known 
as “Design of Experiments” (DoE). DoE is an excellent tool 
that allows pharmaceutical scientists to systematically 
manipulate factors according to a pre-specified design. A 
good design is based on sound cognition of product and 
effective management of whole process during 
manufacturing. DoE studies work together with mechanism-
based studies to achieve better product and process 
understanding. 
DoE is a reasonable method to determine the relationship 
between the inputs and outputs of a process. It can help 
identify optimal conditions, CMAs, CPPs, and, ultimately, the 
Design Space. It is wise to establish a Design Space through 
DoE for multivariate experiments. ICH Q8 defines the Design 
Space as “the multidimensional combination and interaction 
of input variables (e.g., material attributes) and process 
parameters that have been demonstrated to provide 
assurance of quality” . It has been reported that there is no 
need to hand over supplements to revise (e.g., widen) the 
acceptance criteria to FDA if the changes are within the 
Design Space. Design of experiments (DOE) is a structured 
and organized method to determine the relationship among 
factors that influence outputs of a process. It has been 
suggested that DOE can offer returns that are four to eight 
times greater than the cost of running the experiments in a 
fraction of the time. A methodology for designing 
experiments was proposed by Ronald A. Fisher, in his 
innovative book.The Design of Experiments (1935). 
Application of DOE in QbD helps in gaining maximum 
information from a minimum number of experiments. When 
DOE is applied to a pharmaceutical process, factors are the 
raw material attributes (e.g., particle size) and process 
parameters (e.g., speed and time), while outputs are the 
critical quality attributes such as blend uniformity, tablet 
hardness, thickness, and friability. As each unit operation has 
many input and output variables as well as process 
parameters, it is impossible to experimentally investigate all 
of them. Scientists have to use prior knowledge and risk 
management to identify the key input and output variables 
and process parameters to be investigated by DOE. DOE 
results can help identify optimal conditions, the critical 
factors that most influence CQAs and those who do not, as 
well as details such as the existence of interactions and 
synergies between factors . One Factor at a time and Design 
of experiments. 
So far, a number of studies have been launched in the drug 
delivery systems after QbD initiative was claimed, as 
summarized in . It has been demonstrated that DoE is 
effective in the design of different dosage forms and unit 
operations, it can be used more broadly in the near future to 
guarantee high research efficiency with improved product 
quality. 
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7) Design-space 
ICH Q8 defines design space as, the multidimensional 
combination and interaction of input variables (material 
attributes) and process parameters that have been 
demonstrated to provide assurance of quality. Moving out of 
the design space is considered to be a change and would 
normally initiate a regulatory post-approval change process. 
The design space is proposed by the applicant and is subject 
to regulatory assessment and approval. Design space is 
potentially scale and equipment dependent, the design space 
determined on the laboratory scale may not be relevant to 
the process at the commercial scale. Therefore, design-space 
verification at the commercial scale becomes essential unless 
it is confirmed that the design space is scale-independent. 
Currently, generic drug sponsors obtain information about 
acceptable ranges for individual CPPs and CMAs at 
laboratory or pilot scales. 
Multidimensional combination of and interaction of input 
variables and process parameters that have been 
demonstrated to provide Quality Assurance.  
ICH Q8 (R1) defines design space as, the multidimensional 
combination and interaction of input variables (material 
attributes) and process parameters that have been 
demonstrated to provide assurance of quality. Moving out of 
the design space is considered to be a change and would 
normally initiate a regulatory post-approval change process. 
The design space is proposed by the applicant and is subject 
to regulatory assessment and approval. Design space is 
potentially scale and equipment dependent, the design space 
determined on the laboratory scale may not be relevant to 
the process at the commercial scale. Therefore, design-space 
verification at the commercial scale becomes essential unless 
it is confirmed that the design space is scale-independent. 
Currently, generic drug sponsors obtain information about 
acceptable ranges for individual CPPs and CMAs at 
laboratory or pilot scales. 
Process Analytical Technology (PAT)- 
PAT has been defined as “A system for designing, analyzing, 
and controlling manufacturing through measurements, 
during processing of critical quality and performance 
attributes of raw and in-process materials and processes, 
with the goal of ensuring final product quality”. The goal of 
PAT is to “enhance understanding and control the 
manufacturing process, which is consistent with our current 
drug quality system: quality cannot be tested into products; 
it should be built-in or should be by design.” The design 
space is defined by the key and critical process parameters 
identified from process characterization studies and their 
acceptable ranges. These parameters are the primary focus 
of on-, in- or at-line PAT applications. In principle, real-time 
PAT assessments could provide the basis for continuous 
feedback and result in improved process robustness. NIR act 
as a tool for PAT and useful in the RTRT (Real Time Release 
Testing) as it monitors the particle size, blend uniformity, 
granulation, content uniformity, polymorphism , dissolution 
and monitoring the process online, at the line and offline, 
thus it reduces the release testing of the product 
PAT as an important tool of QbD 
PAT is defined as “Tools and systems that utilize real-time 
measurements, or rapid measurements during processing, of 
evolving quality and performance attributes of in-process 
materials to provide information to ensure optimal 
processing to produce final product that consistently 
conforms to established quality and performance standards”. 
ICH Q8 identifies the use of PAT to ensure that the process 
remains within an established Design Space. 
The concept originates from the desire of the regulators to 
shift control of product quality toward a science-based 
approach that explicitly attempts to reduce the risk to 
patients by controlling the manufacturing based on 
understanding of the process. 
PAT REGULATORY APPROACH  
One goal of this guidance is to tailor the Agency's usual 
regulatory scrutiny to meet the needs of PAT-based 
innovations that  
(1) Improve the scientific basis for establishing regulatory 
specifications,  
(2) Promote continuous improvement, and  
(3) Improve manufacturing while maintaining or improving 
the current level of product quality. To be able to do this, 
manufacturers should communicate relevant scientific 
knowledge to the Agency and resolve related technical issues 
in a timely manner. Our goal is to facilitate a consistent 
scientific regulatory assessment involving multiple Agency 
offices with varied responsibilities. 
This guidance provides a broad perspective on our proposed 
PAT regulatory approach. Close communication between the 
manufacturer and the Agency’s PAT review and inspection 
staff will be a key component in this approach. We anticipate 
that communication between manufacturers and the Agency 
may continue over the life cycle of a product and that 
communication will be in the form of meetings, telephone 
conferences, and written correspondence. 
All marketing applications, amendments, or supplements to 
an application should be submitted to the appropriate CDER 
or CVM division in the usual manner. When consulting with 
the Agency, manufacturers may want to discuss not only 
specific PAT plans, but also thoughts on a possible regulatory 
path. Information generated from research on an existing 
process, along with other process knowledge, can be used to 
formulate and communicate implementation plans to Agency 
staff. In general, PAT implementation plans should be risk 
based. We are proposing the following possible 
implementation plans, where appropriate: PAT can be 
implemented under the facility's own quality system. CGMP 
inspections by the PAT Team or PAT certified Investigator 
can precede or follow PAT implementation. 
 Contains Nonbinding Recommendations A supplement (CBE, 
CBE-30 or PAS) can be submitted to the Agency prior to 
implementation, and, if necessary, an inspection can be 
performed by a PAT Team or PAT certified Investigator 
before implementation. A comparability protocol5 can be 
submitted to the Agency outlining PAT research, validation 
and implementation strategies, and time lines. Following 
approval of this comparability protocol by the Agency, one or 
a combination of the above regulatory pathways can be 
adopted for implementation. To facilitate adoption or 
approval of a PAT process, manufacturers may request a 
preoperational review of a PAT manufacturing facility and 
process by the PAT Team (see ORA Field Management 
Directive No.135)6 by contacting the FDA Process Analytical 
Technology Team at the address given above. It should be 
noted that when certain PAT implementation plans neither 
affect the current process nor require a change in 
specifications, several options can be considered. 
Manufacturers should evaluate and discuss with the Agency 
the most appropriate option for their situation. 
 
Bhise et al                                                                                                       Journal of Drug Delivery & Therapeutics. 2019; 9(3-s):1137-1146 
ISSN: 2250-1177                                                                                  [1146]                                                                                    CODEN (USA): JDDTAO 
REFERENCES 
1) ICH Q8 (R2), Pharmaceutical Development, Part I: 
Pharmaceutical Development, (2009). 
2) ICH Q9, Quality Risk Management, (2005). 
3) ICH Q10, Pharmaceutical Quality Systems, (2008). 
4) US Food and Drug Administration (FDA), Department of Health 
and Human Services, Pharmaceutical Quality for the 21st 
Century A Risk-Based Approach Progress Report, (2007). 
5) US Food and Drug Administration (FDA), Guidance for industry 
PAT-A framework for innovative pharmaceutical manufacturing 
and quality assurance, FDA, Washington, DC, USA, (2004). 
6) Lawrence, X. Raw, A.Lionberger, R. Rajagopalan, R. Lee, L. etal. 
U.S. FDA question-based review for generic drugs: A new 
pharmaceutical quality assessment system, J. Generic Med., 
4:239–248 (2007). 
7) Rathore, A.S. Winkle, H. Quality by design for 
biopharmaceuticals, Nat Biotechnol., 27: 27- 34 (2009). 
8) Nadpara, N.P. Thumar, R.V. Kalola, V.N. Patel, P.B. Quality By 
Design (Qbd) : A Complete Review, Int. J. Pharm. Sci. Rev. Res., 17: 
20-28(2012). 
9) Gawade, A. Chemate, S. Kuchekar, A. Pharmaceutical Quality by 
Design: A New Approach in Product Development. Res Rev: J 
Pharm. Pharm Sci., 2: 5-12 (2013). 
10) Juran, J.M. Juran on quality by design The new steps for planing 
quality into goods and services, Revised Edition, free press, 
newyork, 1992,1-2. 
11) Purohit, P.J. Shah, K.V. Quality By Design (Qbd): New Parameter 
For Quality Improvement & Pharmaceutical Drug 
Development,Pharma Science MonitorInt J Pharm Sci.,4: 1-19 
(2013). 
12) Roy, S. Quality by design: A holistic concept of building quality in 
pharmaceuticals, Int J Pharm Biomed Res., 3: 100-108 (2012). 
13) Glodek, M. Liebowitz, S. McCarthy, R. McNally, G. Oksanen, C. 
Schultz, T. et al. Pharm. Eng., 26: 1-11 (2006). 
14) Siegfried, A.Suzzia,D.Radekea, C.Khinasta, J.G. An integrated 
Quality by Design (QbD) approach towards design space 
definition of a blending unit operation by Discrete Element 
Method (DEM) simulation, Eur J Pharm Sci.,42: 106–115 (2011). 
15) Nwoko V.E. Quality By Design (Qbd): Manufacturing And 
Product Quality Of generics Drugs Perspective, J Glob Tre Pharm 
Sci., 4: 1257-1262 (2013). 
16) Shajeeya, A.S. Viswanath, A. Srinivasa, P. Quality By Design - 
Novelty In Pharmaceuticals, World J Pharma Res., 2: 1409-1422 
(2013). 
17) Shah, R.B. Quality by Design in Pharmaceutical Manufacturing, 
U.S. Food and Drug Administration (2009). 
18) Bhasin, R.Ghosh, P. Design and development of ondansetron 
orally disintegrating tablets and its optimization using design of 
experiment, Int J Pharm Sci Res.,3: 840-847 (2012). 
19) Ian House Process Understanding: for Scale-up and 
Manufacturing method of Active Ingredients, First edition, 
Wiley-VCH Ver lag GMb H&Co. KGaA (2011). 
20) Food and Drug Administration. Final Report on Pharmaceutical 
cGMPs for the 21st Century – A Risk Based Approach, 
http://www.fda.gov/ cder/ gmp/ gmp 2004/ GMP_ final report 
2004.htm. 
21) Nasr, N., Risk Based CMC Review Paradigm. Advisory Committee 
for Pharmaceutical Science Meeting, July, 20-21. 2004. 
22) US Food and Drug Administration. Guidance forIndustry. PAT—
A Framework for Innovative Pharmaceutical Manufacturing and 
Quality Assurance. Pharmaceutical cGMPs. Rockville, MD, Sept., 
1–21. 2004. 
23) Delasko, J.M., Cocchetto, D.M., Burke. L.B., Target Product Profile: 
Beginning Drug Development with the End in Mind. Update, 
January/February, Issue 1, ,http://www.fdli.org. 
24) Food and Drug Administration CDER. Draft Guidance for 
Industry and Review Staff: TargetProduct Profile- A Strategic 
Development Tool (March 2007). 
25) Food and Drug Administration Office of Generic Drugs. Model 
Quality Overall Summary for IR Product, http:// www.fda.gov/ 
cder/ ogd/ OGD_Model-QoS_IR_Product.pdf (AccessedMarch 31, 
2006) 
26) US Food and Drug Administration. Guidance for industry: Q8 
Pharmaceutical Development, US Department of Health and 
Human Service, FDA, Rockville, MD, May 2006. 
27) Amidon, G.E., Hageman, X. He, M.J., in: Abraham, D.J, (Eds), 
Burgers Medicinal Chemistry and Drug Discovery, Vol.2, Wiley- 
Interscience, New York 2004. 
28) US Food and Drug Administration. Guidance for Industry: Q9 
Quality Risk Management, US Department of Health and Human 
Service, FDA, Rockville, MD, June 2006. 
29) US Food and Drug Administration, Pharmaceutical cGMPs for the 
21st century: A Risk Based Approach, FDA, Rockville, MD, 
August2002. http://www.fda.ov/oc/guidance/gmp.html. 
 
 
 
